Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PHIO
stocks logo

PHIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.450
-47.06%
--
--
-0.290
-29.27%
--
--
-0.300
-33.33%
Estimates Revision
The market is revising No Change the revenue expectations for Phio Pharmaceuticals Corp. (PHIO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.82%.
EPS Estimates for FY2025
Revise Downward
down Image
-12.32%
In Past 3 Month
Stock Price
Go Down
down Image
-33.82%
In Past 3 Month
Wall Street analysts forecast PHIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHIO is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PHIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHIO is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.350
sliders
Low
14.00
Averages
14.00
High
14.00
Current: 1.350
sliders
Low
14.00
Averages
14.00
High
14.00
H.C. Wainwright
H.C. Wainwright
initiated
$14
2025-06-05
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$14
2025-06-05
initiated
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$4
2025-04-08
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$4
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Vernon Bernardino
Strong Buy
Reiterates
$4
2025-02-19
Reason
HC Wainwright & Co.
Vernon Bernardino
Price Target
$4
2025-02-19
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Phio Pharmaceuticals Corp (PHIO.O) is -1.17, compared to its 5-year average forward P/E of -2.40. For a more detailed relative valuation and DCF analysis to assess Phio Pharmaceuticals Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.40
Current PE
-1.17
Overvalued PE
6.25
Undervalued PE
-11.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.07
Undervalued EV/EBITDA
-0.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.26
Current PS
0.00
Overvalued PS
0.84
Undervalued PS
-0.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PHIO News & Events

Events Timeline

Sign Up For More Events
no data image
No Data
Sign Up For More Events

News

[object Object]
Preview
2.0
11-04TipRanks
Three Penny Stocks to Keep an Eye on as of November 4, 2025

  • Penny Stocks to Watch: Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are highlighted as top penny stocks to monitor on November 4, 2025, based on their high Dollar Volume and market activity.

  • Generation Essentials Group: This France-based media company saw a Dollar Volume of $308 million and a 123% stock price increase after announcing a share repurchase program and plans to acquire hotels globally.

  • Phio Pharmaceuticals: The biotech firm experienced a Dollar Volume of $301.44 million despite a 9.3% decline in stock price, following positive trial results for its cancer treatment, which initially surged by nearly 75%.

  • Caribou Biosciences: With a Dollar Volume of $166.10 million, Caribou's stock reached a 52-week high after positive analyst ratings and promising data on its CRISPR gene-editing therapies for difficult-to-treat cancers.

[object Object]
Preview
9.0
11-04Benzinga
What’s Driving the Surge in Phio Pharmaceuticals Stock Today?

  • Phio Pharmaceuticals Update: Shares of Phio Pharmaceuticals Corp. rose significantly after announcing positive results from its ongoing Phase 1b trial for treating cutaneous squamous cell carcinoma (cSCC), with one patient achieving 100% tumor clearance.

  • Trial Results: Out of 18 patients treated, six showed complete responses, while others demonstrated varying degrees of tumor clearance, and no patients experienced clinical progression of the disease.

  • Stock Performance: The stock surged over 30% on Monday, trading at $2.73, and is currently above its 50-day and 200-day moving averages, indicating a strong upward trend.

  • Market Sentiment: The bullish sentiment surrounding Phio Pharmaceuticals may attract further investor interest, although the stock faces potential resistance near its 52-week high of $9.78.

[object Object]
Preview
4.5
11-04TipRanks
Monday's Major Stock Market Highlights: Morning News Summary!

  • Market Overview: Traders are encouraged to explore significant stock market stories as the week begins, highlighting key happenings to watch for on Monday.

  • Source for More Information: Additional top stock market stories can be found at TipRanks, providing further insights for traders.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Phio Pharmaceuticals Corp (PHIO) stock price today?

The current price of PHIO is 1.35 USD — it has increased 4.65 % in the last trading day.

arrow icon

What is Phio Pharmaceuticals Corp (PHIO)'s business?

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

arrow icon

What is the price predicton of PHIO Stock?

Wall Street analysts forecast PHIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHIO is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Phio Pharmaceuticals Corp (PHIO)'s revenue for the last quarter?

Phio Pharmaceuticals Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Phio Pharmaceuticals Corp (PHIO)'s earnings per share (EPS) for the last quarter?

Phio Pharmaceuticals Corp. EPS for the last quarter amounts to -0.44 USD, decreased -71.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Phio Pharmaceuticals Corp (PHIO)'s fundamentals?

The market is revising No Change the revenue expectations for Phio Pharmaceuticals Corp. (PHIO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -33.82%.
arrow icon

How many employees does Phio Pharmaceuticals Corp (PHIO). have?

Phio Pharmaceuticals Corp (PHIO) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Phio Pharmaceuticals Corp (PHIO) market cap?

Today PHIO has the market capitalization of 14.53M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free